Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bafisontamab - EpimAb Biotherapeutics

Next Previous
Drug Profile

Bafisontamab - EpimAb Biotherapeutics

Alternative Names: EMB-01

Latest Information Update: 14 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpimAb Biotherapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Gastrointestinal cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jul 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA, China (IV) (EpimAb Biotherapeutics pipeline, July 2022)
  • 07 Jun 2022 The US FDA approves IND application for bafisontamab phase Ib/II trial in Non-small cell lung cancer
  • 07 Jun 2022 EpimAb Biotherapeutics plans a phase Ib/II trial for Non-small cell lung cancer (Combination therapy) (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top